Evidence map›Paper›PMID 31633763›Full record

ArticleInternational immunology2020

A suppressive oligodeoxynucleotide expressing TTAGGG motifs modulates cellular energetics through the mTOR signaling pathway.

Volkan Yazar, Gizem Kilic, Ozlem Bulut, Tugce Canavar Yildirim, Fuat C Yagci, Gamze Aykut, Dennis M Klinman, Mayda Gursel, Ihsan Gursel

Abstract read
In one paragraph

Article in International immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Treg-inducing capacity of genomic DNA ofAllergy and asthma proceedings · 2020
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Volkan YazarThorlab-Therapeutic Oligodeoxynucleotide Research Laboratory, Department of Molecular Biology and Genetics, Faculty of Science, Ihsan Dogramaci Bilkent University, Ankara, Turkey.
Gizem KilicThorlab-Therapeutic Oligodeoxynucleotide Research Laboratory, Department of Molecular Biology and Genetics, Faculty of Science, Ihsan Dogramaci Bilkent University, Ankara, Turkey.
Ozlem BulutThorlab-Therapeutic Oligodeoxynucleotide Research Laboratory, Department of Molecular Biology and Genetics, Faculty of Science, Ihsan Dogramaci Bilkent University, Ankara, Turkey.
Tugce Canavar YildirimThorlab-Therapeutic Oligodeoxynucleotide Research Laboratory, Department of Molecular Biology and Genetics, Faculty of Science, Ihsan Dogramaci Bilkent University, Ankara, Turkey.
Fuat C YagciThorlab-Therapeutic Oligodeoxynucleotide Research Laboratory, Department of Molecular Biology and Genetics, Faculty of Science, Ihsan Dogramaci Bilkent University, Ankara, Turkey.
Gamze AykutThorlab-Therapeutic Oligodeoxynucleotide Research Laboratory, Department of Molecular Biology and Genetics, Faculty of Science, Ihsan Dogramaci Bilkent University, Ankara, Turkey.
Dennis M KlinmanImmune Modulation Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Mayda GurselDepartment of Biological Sciences, Middle East Technical University, Ankara, Turkey.
Ihsan GurselThorlab-Therapeutic Oligodeoxynucleotide Research Laboratory, Department of Molecular Biology and Genetics, Faculty of Science, Ihsan Dogramaci Bilkent University, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune-mediated inflammation must be down-regulated to facilitate tissue remodeling during homeostatic restoration of an inflammatory response. Uncontrolled or over-exuberant immune activation can cause autoimmune diseases, as well as tissue destruction. A151, the archetypal example of a chemically synthesized suppressive oligodeoxynucleotide (ODN) based on repetitive telomere-derived TTAGGG sequences, was shown to successfully down-regulate a variety of immune responses. However, the degree, duration and breadth of A151-induced transcriptome alterations remain elusive. Here, we performed a comprehensive microarray analysis in combination with Ingenuity Pathway Analysis (IPA) using murine splenocytes to investigate the underlying mechanism of A151-dependent immune suppression. Our results revealed that A151 significantly down-regulates critical mammalian target of rapamycin (mTOR) activators (Pi3kcd, Pdpk1 and Rheb), elements downstream of mTOR signaling (Rps6ka1, Myc, Stat3 and Slc2a1), an important component of the mTORC2 protein complex (Rictor) and Mtor itself. The effects of A151 on mTOR signaling were dose- and time-dependent. Moreover, flow cytometry and immunoblotting analyses demonstrated that A151 is able to reverse mTOR phosphorylation comparably to the well-known mTOR inhibitor rapamycin. Furthermore, Seahorse metabolic assays showed an A151 ODN-induced decrease in both oxygen consumption and glycolysis implying that a metabolically inert state in macrophages could be triggered by A151 treatment. Overall, our findings suggested novel insights into the mechanism by which the immune system is metabolically modulated by A151 ODN.

Indexed as

Amino Acid MotifsAnimalsCells, CulturedImmunosuppressive AgentsMiceMice, Inbred C57BLOligodeoxyribonucleotidesPhosphorylationSignal TransductionTOR Serine-Threonine KinasesImmunosuppressive AgentsMTOR protein, humanOligodeoxyribonucleotidesTOR Serine-Threonine KinasesA151 ODNimmunometabolismimmunosuppressionmicroarray

Identifiers

PMID31633763
PMCPMC7185194

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.